- Home
- INVE vs ACOG Comparison
INVE vs ACOG Comparison
Compare INVE & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- ACOG
- Stock Information
- Founded
- INVE 1990
- ACOG 2000
- Country
- INVE United States
- ACOG Canada
- Employees
- INVE N/A
- ACOG N/A
- Industry
- INVE Computer peripheral equipment
- ACOG
- Sector
- INVE Technology
- ACOG
- Exchange
- INVE Nasdaq
- ACOG Nasdaq
- Market Cap
- INVE 85.9M
- ACOG 80.3M
- IPO Year
- INVE 1997
- ACOG N/A
- Fundamental
- Price
- INVE $3.62
- ACOG $8.72
- Analyst Decision
- INVE Strong Buy
- ACOG Strong Buy
- Analyst Count
- INVE 2
- ACOG 1
- Target Price
- INVE $5.50
- ACOG $20.00
- AVG Volume (30 Days)
- INVE 42.8K
- ACOG 62.8K
- Earning Date
- INVE 11-06-2025
- ACOG 11-14-2025
- Dividend Yield
- INVE N/A
- ACOG N/A
- EPS Growth
- INVE N/A
- ACOG N/A
- EPS
- INVE 3.12
- ACOG N/A
- Revenue
- INVE $23,538,000.00
- ACOG $4,586,341.00
- Revenue This Year
- INVE N/A
- ACOG N/A
- Revenue Next Year
- INVE $9.98
- ACOG $149.89
- P/E Ratio
- INVE $1.17
- ACOG N/A
- Revenue Growth
- INVE N/A
- ACOG N/A
- 52 Week Low
- INVE $2.86
- ACOG $3.75
- 52 Week High
- INVE $4.29
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- INVE 46.98
- ACOG 46.54
- Support Level
- INVE $3.73
- ACOG $8.01
- Resistance Level
- INVE $3.85
- ACOG $10.00
- Average True Range (ATR)
- INVE 0.15
- ACOG 0.50
- MACD
- INVE -0.02
- ACOG 0.12
- Stochastic Oscillator
- INVE 11.11
- ACOG 38.49
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.